Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138:429–34.

Article  PubMed  Google Scholar 

Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011:623924.

Article  PubMed  PubMed Central  Google Scholar 

Schaefer L, Comfere N, Sokumbi O. Development of cutaneous t-cell lymphoma following biologic treatment: a systematic review. Am J Clin Dermatol. 2023;24:153–64.

Article  PubMed  Google Scholar 

Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, et al. Cutaneous T cell lymphoma. Nat Rev Dis Primers. 2021;7:61.

Article  PubMed  Google Scholar 

Wang X, Wang W, Vega F, Quesada AE. Aggressive mediastinal lymphomas. Semin Diagn Pathol. 2024;41:125–39.

Article  PubMed  Google Scholar 

Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013;98:1702–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel RP, Ghilardi G, Porazzi P, Yang S, Qian D, Pajarillo R, et al. Clinical development of Senza5TM CART5: a novel dual population CD5 CRISPR-Cas9 knocked out anti-CD5 chimeric antigen receptor T cell product for relapsed and refractory CD5 + nodal T-cell lymphomas. Blood. 2022;140:1604–5.

Article  Google Scholar 

Raikar SS, Fleischer LC, Moot R, Fedanov A, Paik NY, Knight KA, et al. Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines. Oncoimmunology. 2018;7:e1407898.

Article  PubMed  Google Scholar 

Angelos MG, Patel RP, Ruella M, Barta SK. Progress and pitfalls of chimeric antigen receptor T cell immunotherapy against T cell malignancies. Transpl Cell Ther. 2024;30:171–86.

Article  Google Scholar 

Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126:983–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mamonkin M, Mukherjee M, Srinivasan M, Sharma S, Gomes-Silva D, Mo F, et al. Reversible transgene expression reduces fratricide and permits 4-1bb costimulation of CAR T cells directed to T-cell malignancies. Cancer Immunol Res. 2018;6:47–58.

Article  CAS  PubMed  Google Scholar 

Hill L, Rouce RH, Smith TS, Yang L, Srinivasan M, Zhang H, et al. CD5 CAR T-cells for treatment of patients with relapsed/refractory CD5 expressing T-cell lymphoma demonstrates safety and anti-tumor activity. Biol Blood Marrow Transpl. 2020;26:S237.

Article  Google Scholar 

Feng J, Xu H, Cinquina A, Wu Z, Chen Q, Zhang P, et al. Treatment of aggressive t cell lymphoblastic lymphoma/leukemia using anti-CD5 CAR T cells. Stem Cell Rev Rep. 2021;17:652–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen W, Shi H, Liu Z, Yang F, Liu J, Zhang L, et al. Single-cell transcriptomics reveals immune reconstitution in patients with R/R T-ALL/LBL treated with donor-derived CD7 CAR-T therapy. Clin Cancer Res. 2023;29:1484–95.

Article  CAS  PubMed  Google Scholar 

Zhang M, Chen D, Fu X, Meng H, Nan F, Sun Z, et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma. Clin Cancer Res. 2022;28:2830–43.

Article  CAS  PubMed  Google Scholar 

Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140:321–34.

CAS  PubMed  Google Scholar 

You F, Wang Y, Jiang L, Zhu X, Chen D, Yuan L, et al. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res. 2019;9:64–78.

CAS  PubMed  PubMed Central  Google Scholar 

Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130:285–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, et al. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017;23:1416–23.

Article  CAS  PubMed  Google Scholar 

Onuoha S, Ferrari M, Bulek A, Bughda R, Manzoor S, Srivastava S, et al. Structure guided engineering of highly specific chimeric antigen receptors for the treatment of T cell lymphomas. Blood. 2018;132:1661.

Article  Google Scholar 

Zhang C, Palashati H, Rong Z, Lin N, Shen L, Liu Y, et al. Pre-depletion of TRBC1 + T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies. Mol Cancer. 2020;19:162.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiang J, Devenport JM, Carter AJ, Staser KW, Kim MY. An off-the-shelf CD2 universal CAR-T therapy for T-cell malignancies. Leukemia. 2023;37:2448–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rasaiyaah J, Georgiadis C, Preece R, Mock U, Qasim W. TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. JCI Insight. 2018;3:e99442.

Article  PubMed  PubMed Central  Google Scholar 

Cárdenas RMV, Brandl SM, Meléndez AV, Schlaak AE, Buschky A, Peters T, et al. Harnessing CD3 diversity to optimize CAR T cells. Nat Immunol. 2023;24:2135–49.

Article  Google Scholar 

Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007;109:4655–62.

Article  CAS  PubMed  Google Scholar 

Pinz KG, Yakaboski E, Jares A, Liu H, Firor AE, Chen KH, et al. Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. Oncotarget. 2017;8:112783–96.

Article  PubMed  PubMed Central  Google Scholar 

Nakashima M, Uchimaru K. CD30 expression and its functions during the disease progression of adult T-cell leukemia/lymphoma. Int J Mol Sci. 2023;24:8731.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yi JH, Kim SJ, Kim WS. Brentuximab vedotin: clinical updates and practical guidance. Blood Res. 2017;52:243–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Y, Chen D, Lu Y, Dong SC, Ma R, Tang WY, et al. A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb. Cancer Gene Ther. 2022;29:167–77.

Article  CAS